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ABSTRACT 
 
Metformin, as one of the first-line clinical anti-diabetic oral drugs for T2DM, 
has been shown to have beneficial effects including decreasing hepatic glucose 
production (HGP), improving insulin sensitivity, and suppressing inflammation, 
primarily in the liver though AMPK pathway. However, the effect of metformin on 
adipose tissue and adipocytes has not been fully investigated, as well as the role of 
PFKFB3/iPFK2, the gene that was shown to be protective against insulin resistance and 
inflammatory response in adipose tissue caused by overnutrition, in beneficial effects of 
metformin.  
In this study, the involvement of PFKFB3/iPFK2 in metformin actions is 
investigated using 3T3-L1 adipocytes, on the aspect of anti-inflammatory effect and 
improvement in insulin sensitivity. In PFKFB3/iPFK2-Control (iPFK2-Ctrl) cells, 
metformin treatment was shown to have significant insulin-sensitizing effect, evidenced 
by an increase in p-Akt/Akt signaling, and some effect on anti-inflammatory response. 
In contrast, insulin sensitivity was not improved, but impaired under metformin 
treatment on PFKFB3/iPFK2-knockdown (iPFK2-KD) adipocytes. Also, metformin did 
not exhibit anti-inflammatory response in iPFK2-KD cells. Meanwhile, the 
phosphorylation of AMPK on control cells was increased with metformin treatment, but 
did not alter in iPFK2-KD cells. These results supported that metformin treatment on 
3T3-L1 adipocytes could increase insulin sensitivity and possibly ameliorate 
inflammatory response, and a disruption of PFKFB3/iPFK2 in adipocytes impairs the 
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insulin-sensitizing and anti-inflammatory effect of metformin, possibly through the 
AMPK pathway.  
Other than drugs, circadian rhythm also takes an important role in regulation of 
adipocyte physiology. Therefore, it is pharmacologically meaningful to investigate the 
timing of drug delivery and the potential differential outcomes. In this study, 3T3-L1 
adipocytes displayed an internal oscillation, evidenced by temporal variations in levels 
of core clock proteins and expression of core clock genes. Furthermore, 3T3-L1 
adipocytes responded circadian time-differently when stimulated with LPS and insulin. 
Anti-inflammatory effect of pioglitazone at ZT19 was more effective than that at ZT7, 
while no significant insulin-sensitizing effect was seen at both time points. 
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NOMENCLATURE 
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AMPK 5’ Adenosine Monophosphate-activated Protein Kinase 
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iPFK2 Inducible 6-phosphofructo-2-kinase 
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JNK c-Jun N-terminal Kinase 
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KD Knockdown 
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MCP-1 Monocyte Chemoattractant Protein-1 
NF-κB Nuclear Factor κB 
PBS Phosphate-Buffered Saline 
PER Period 
PFK-1 Phosphofructokinase-1 
PFK-2/FBPase Phosphofructokinase-2/fructose-2,6-bisphosphatase 
PI3K Phosphatidylinositol-3 Kinase 
Pio Pioglitazone 
PPAR Peroxisome Proliferator-activated Receptor 
Rev-erbα Reverse Erythroblastosis Virus α 
ROS Reactive Oxygen Species 
RT-PCR Reverse Transcription Polymerase Chain Reaction 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gels  
SCN   Suprachiasmatic Nucleus 
T2DM Type 2 Diabetes Mellitus 
TG Triglyceride 
TLR4 Toll-like Receptor 4 
TNFα Tumor Necrosis Factor α 
TZD   Thiazolidinediones 
WAT   White Adipose Tissue 
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1. INTRODUCTION  
 
Adipose tissue plays an important role as an endocrine organ in metabolic control 
through the synthesis and secretion of adipokines. Studies have shown that chronic 
inflammation of the adipose tissue is highly related to insulin resistance as well as 
metabolic disorders including obesity and Type 2 Diabetes Mellitus (T2DM) [1]. 
With the increasing incidence of T2DM in the last three decades, metformin, as 
one of the first-line clinical anti-diabetic oral drugs for T2DM, has been shown to have 
beneficial effects including decreasing hepatic glucose production, improving insulin 
sensitivity, and suppressing inflammation, primarily in the liver though AMP-activated 
protein kinase (AMPK) pathway [2, 3]. However, the effect and mechanism of 
metformin on adipose tissue and adipocytes has not been fully investigated, as well as 
the role of PFKFB3/iPFK2, the gene that has been shown to be protective against insulin 
resistance and adipose inflammatory response caused by overnutrition [4], in the 
beneficial effects of metformin.  
At the same time, a growing body of evidence has suggested that a disruption in 
circadian biological clock can contribute to the increased prevalence of obesity and 
T2DM [5, 6]. Adipose tissue, as one of the major peripheral tissues that display 
oscillations of circadian rhythms [7, 8], plays an essential role in metabolic regulation 
and exhibits insulin resistance and inflammatory response in overnutrition-related 
diseases such as obesity and T2DM [9, 10]. 
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Therefore, the major goal of this study is to investigate the involvement of 
PFKFB3/iPFK2 in metformin actions using 3T3-L1 adipocytes, on the aspect of anti-
inflammatory effect and improvement in insulin sensitivity; and to identify the circadian 
rhythm in adipocytes and whether treating adipocytes with drugs at different circadian 
times could result in differential beneficial effects. 
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2. LITERATURE REVIEW 
 
2.1 Inflammation, insulin resistance, and T2DM 
Inflammation has been categorized into two subtypes based on its characteristics. 
When injured, the body responses to the injury through acute inflammation with 
symptoms including swelling, redness, fever and pain. This is the classic type of 
inflammation that is a short-term adaptive action that is essential for tissue repair and 
tissue regeneration [11]. In recent years, the other type of inflammation, low-grade 
chronic inflammation has been studied more heavily for that it is metabolically triggered 
inflammation that ties closely with metabolic disorders such as obesity, T2DM and 
cardiovascular diseases [11, 12].  
Low-grade chronic inflammation is displayed with increased inflammatory 
cytokines production, abnormal secretion of adipokines, as well as elevated plasma lipid 
levels [12, 13]. The association between chronic inflammation and obesity was first 
evidenced about three decades ago by the overexpression of proinflammatory cytokine 
tumor necrosis factor-α (TNF-α) in adipose tissue of obese mice [14], and in the adipose 
tissue and muscle in obese humans [12, 15]. In later research, this close association 
between obesity and inflammatory response has been further indicated in obese animal 
models and human studies, evidenced by activation of inflammatory signaling pathways 
with elevated plasma levels of inflammatory cytokines such as TNF-α and interleukin 
(IL)-6, increased production and secretion of leptin from adipose tissue, as well as high 
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levels of other inflammatory markers [16-18]. The expression levels of these major 
factors link metabolic regulation together with inflammatory responses. 
An overproduction of inflammatory cytokines contributes to insulin resistance. 
Insulin is a crucial regulatory hormone which facilitates glycolysis and uptake of glucose 
by peripheral tissues, and stimulates lipid synthesis and decreases triglyceride (TG) 
breakdown [19]. Insulin resistance is a condition when these peripheral tissues, including 
liver, adipose tissue and skeletal muscle, cannot respond to insulin normally for it to 
perform its regulatory action in nutrient metabolism, which is a key contributor to 
metabolic disorders [1, 19].  
In healthy individuals, insulin functions upon binding to insulin receptor on the 
cell membrane in target tissues. Insulin receptor will become phosphorylated and also 
stimulates the tyrosine phosphorylation of some other substrates including insulin 
receptor substrate (IRS) proteins, which will then activate Phosphatidylinositol-3 Kinase 
(PI3K)-Akt signaling pathway, a crucial step in mediating downstream insulin signaling 
action [11, 12, 20]. In adipocytes and muscle cells, phosphorylation of Akt stimulates 
intracellular insulin-responsive glucose transporter 4 (GLUT4) to translocate to cell 
surface to enhance the uptake of glucose [21-23]. Inhibitory serine phosphorylation of 
IRS-1 negatively impacts the tyrosine phosphorylation and the reaction to insulin of 
IRS-1.  
Obesity-associated high levels of TNF-α, free fatty acid (FFA) and endoplasmic 
reticulum (ER) stress will activate inflammatory kinases including c-Jun N-terminal 
kinase (JNK) and IκB kinase (IKK). JNK, and possibly IKK, will stimulate the 
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inhibitory serine phosphorylation of IRS-1 to inhibit insulin signaling pathway [11, 12, 
19]. JNK activation further stimulates increased cytokine levels such as IL-1β and TNF-
α. Other than possible phosphorylation of IRS-1 on serine residues and impairment of 
islet cell function, IKKβ also activates Nuclear Factor κB (NF-κB), which is an 
important transcription factors that triggers production of several  inflammatory 
mediators through synthesis of its target gene products [24]. At the same time, ER stress 
generated by overnutrition will cause high production level of  reactive oxygen species 
(ROS) and leads to oxidative stress, the feature underlying obesity, to enhance 
inflammatory response and exacerbate insulin resistance [11, 12]. This mechanism of the 
causative link between inflammatory pathways and insulin resistance is illustrated in 
Figure 1.  
 
2.2 Adipose tissue and inflammatory response 
In the traditional notion, adipose tissue simply serves as energy storage pool 
which stores and releases energy when needed. However, in addition to its inert function 
of energy storage, adipose tissue is now commonly considered a dynamic endocrine 
organ that plays a regulatory role in metabolic homeostasis. It functions through the 
production and secretion of adipokines including leptin, adiponectin and resistin, as well 
as proinflammatory and anti-inflammatory cytokines and chemokines including TNF-α, 
IL-6, IL-10 and CPT1 [13].  
A lot of evidence has suggested that adipose tissue plays an important part in 
metabolic disorders and that adipose dysfunction ties obesity closely to the pathogenesis 
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Figure 1. Molecular pathway integrating inflammatory response with insulin 
action. [11, 12, 20] 
 
 
of T2DM through development of insulin resistance. When obesity occurs due to 
nutrient surplus, the inflammatory response predominantly resides in the adipose tissue, 
where inflammatory mediators are generated [11]. Therefore, adipose tissue has been 
studied extensively in the aspect of metabolic regulation.  
As an individual becomes obese, the adipocytes will enlarge and circulating FFA 
and glycerol levels are elevated due to increased breakdown of TG [25]. Increased FFAs 
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will reduce glucose uptake and glucose oxidation, increase hepatic glucose output, as 
well as inhibiting insulin signaling through serine phosphorylation of IRS-1 [23]. Leptin 
is a peptide hormone secreted by adipocytes, and its primary role is appetite control.  
Another hormone secreted by adipose tissue is adiponectin, which can enhance insulin 
sensitivity and reduce inflammatory response through decreasing TNF-α production and 
activity, inhibiting IL-6 production, and stimulating FFA oxidation and anti-
inflammatory IL-10 expression. Even though it is secreted predominantly by adipocytes, 
adiponectin levels tend to decrease with increased fat mass in obese individuals; in 
patients with T2DM, adiponectin levels decreases significantly [9, 13]. Resistin is 
another adipocyte-secreted molecule which has recently been found to be increased with 
obesity and indicated to be proinflammatory through multiple possible mechanisms [26]. 
As mentioned above, TNF-α is overexpressed in white adipose tissue (WAT) in 
obese subjects, and can activate inflammatory cascade and act as inhibitors of the insulin 
signaling pathway directly via inhibitory phosphorylation of IRS-1 and indirectly via 
activation of JNK and NF-κB inflammatory pathway.  There is some evidence that TNF-
α may have impact on downregulation of adiponectin production. In addition to TNF-α, 
proinflammatory markers that WAT produces with the enlargement of adipocytes 
include cytokines like IL-1β and IL-6, and chemokines such as monocyte 
chemoattractant protein-1 (MCP-1) [27-29]. Diabetic patients have been shown to have 
elevated IL-6 levels, which is associated with impairment in insulin sensitivity. Even 
though IL-6-deficient mice exhibit insulin resistance and diabetes, IL-6 is still 
commonly considered as a proinflammatory cytokine. In insulin-resistant mice, IL-1β 
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mRNA expression in epididymal fat and circulating IL-1β levels are increased [30]. 
MCP-1 mRNA expression has been shown to increase in obese mice in response to 
adiposity, and contribute to insulin resistance and macrophage infiltration in adipose 
tissue [31]. Toll-like receptor-4 (TLR4) is an immune sensor that has been reported to 
increase in obese tissues to induce inflammatory response. FFAs are considered to 
contribute to TLR signaling [32].  Other than adipocytes, macrophages are also a 
component of adipose tissue and are accumulated in the presence of obesity. Like 
adipocytes, macrophages contribute to the upregulation of TNF-α and IL-6 as well [13]. 
However, this thesis will mainly focus on the adipocytes. The metabolism described 
above is illustrated in Figure 2. 
The most widely utilized cell lines in the study of adipocytes are 3T3-L1 and 
3T3-F442A, which are isolated from mice embryos. Mature adipocytes are differentiated 
from fibroblast-like preadipocytes through differentiation stage under inducing agents. 
At confluence, preadipocytes will gradually experience morphological changes and 
convert into round shape, accumulate lipid droplets, as well as display biological 
characteristics such as gene expression of mature adipocytes of live adipose tissue [33, 
34]. 
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Figure 2. Potential mechanism of adipose tissue inflammation in overnutrition-
induced obesity. [11, 29, 30] 
 
 
2.3 Metformin, pioglitazone and T2DM 
2.3.1 Metformin 
Metformin has been one of the most widely used first-line clinical anti-diabetic 
oral drugs for T2DM starting from its initial medical use. In clinical trials, obese patients 
who are given metformin have attained lower fasting plasma glucose and lower levels of 
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HbA1c [35]. Metformin is also shown to be effective in preventing or at least delaying 
progression of diabetes and associated complications among people who are at high risk 
[2, 36]. In addition to ameliorating insulin resistance, the beneficial effects of metformin 
in targeting inflammation could be utilized as a preventative and therapeutic approach to 
treatment in diabetes and its complications [37].  
Currently, most studies on metformin focus on its action in the liver, with its 
effect in reduction of HGP and increase in peripheral glucose uptake with the activation 
of AMPK [3, 38]. However, the effect of metformin in one of the major insulin-sensitive 
tissue, adipose tissue, has not been fully investigated and remains controversial. In 
perivascular adipose tissue, metformin served as an AMPK-activating agent, suppressed 
inflammatory response through inhibition of NF-κB phosphorylation and expression of 
proinflammatory adipocytokines [39]. In some studies, metformin was able to increase 
adiponectin expression level in vivo and in vitro in subcutaneous adipose tissue [40]. Yet 
in another study, metformin was shown to reduce adiponectin protein expression, and 
activated AMPK in 3T3-L1 adipocytes [41]. Meanwhile, when high-fat diet-fed mice 
were treated with metformin, there was no significant improvement in AMPK activation 
and inflammatory response in the adipose tissue [42]. 
2.3.2 Pioglitazone 
 Pioglitazone is among the thiazolidinediones (TZDs) class that are insulin-
sensitizing agents clinically used to treat patients with T2DM. Similar to metformin, 
pioglitazone does not stimulate pancreatic islet cells to secrete more insulin [38]. TZDs 
act through their binding to a specific nuclear transcription factor peroxisome 
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proliferator activated receptor (PPAR)-γ, which is highly expressed in the adipose tissue, 
and in turn take action in insulin sensitivity, lipid metabolism and inflammatory 
response. In adipose tissue, TZDs have been shown to stimulate lipogenesis, glucose 
uptake, fatty acid uptake and glucose oxidation, and suppress insulin-stimulated lipolysis 
[43].  In addition, activation of PPAR-γ accounts for suppressed NF-κB  to inhibit 
production of proinflammatory cytokines [11]. It has been established that pioglitazone 
treatment can ameliorate insulin resistance and improve glycemic control and lipid 
profile, despite an increase in body fat mass [44].  
 
2.4 PFKFB3/iPFK2 and adipocyte physiology 
 PFKFB3 is a gene that encodes inducible 6-phosphofructo-2-kinase (iPFK2), 
which is an inducible isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphotase 
(PFK-2/FBPase). PFK-2/FBPase regulates the production and degradation of fructose 
2,6-bisphosphotate (F2,6BP), which is a potent allosteric activator of 6-phosphofructo-1-
kinase (6PFK1), the rate-limiting enzyme for glycolysis pathway [45-48]. Therefore, 
PFKFB3/iPFK2 takes an important part in regulating and stimulating glucose 
metabolism.  
 Studies have shown that PFKFB3/iPFK2 is highly expressed in adipose tissue of 
human and mice and plays a role in metabolic regulation. With glucose uptaken into 
adipocytes, PFKFB3/iPFK2 stimulates the synthesis of F2,6BP, which in turn activates 
6PFK1 potently. This catalyzes the production of glycolytic products: glycerol-3-
phosphate (G3P) and pyruvate. Pyruvate metabolism generates acetyl-CoA, which will 
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be used for FFA synthesis. FFAs digested from diet transport into the cells through fatty 
acid transporters. Together with FFA generated from acetyl-CoA and G3P, they are 
converted to triglycerides to be stored in the adipocytes/adipose tissue [49]. This 
regulatory function of PFKFB3/iPFK2 is illustrated in Figure 3. 
 
 
 
Figure 3. PFKFB3/iPFK2 regulates adipocyte glucose and lipid metabolism. 
Modified based on Guo, et al. [49] 
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In support of this mechanism, studies suggested that under high-fat diet, a 
disruption of PFKFB3/iPFK2 in mice led to less weight gain in comparison to wild-type 
littermates, yet resulted in more severe adipose tissue dysfunction, adipose inflammatory 
response, and systemic insulin resistance. A knockdown of PFKFB3/iPFK2 in 3T3-L1 
adipocytes showed similar outcomes evidenced by activated JNK and NF-κB pathways, 
increased proinflammatory cytokine expression including TNF-α and IL-6, decreased 
adiponectin expression and decreased insulin signaling, suggesting that PFKFB3/iPFK2 
serves as a link between adipocyte nutrient metabolism and inflammatory response [4].  
When PFKFB3/iPFK2 is disrupted, glycolysis is suppressed due to lack of 
production of the rate-limiting enzyme 6PFK1. As a result, lipogenesis and synthesis and 
storage of triglyceride using glucose as a source are impaired. Meanwhile, this leads to a 
compensatory elevated fatty acid oxidation, contributing to increased ROS production, 
which is associated with elevated proinflammatory cytokine expression through 
phosphorylation of JNK1 and NF-κB [4]. Therefore, PFKFB3/iPFK2 contributes to the 
anti-inflammatory response in adipocytes through regulation of fuel metabolism and 
inhibition of undesired high levels of fatty acid oxidation. 
 
2.5 Circadian rhythm in adipocytes 
 The metabolism of adipose tissue is not simply affected by dietary factors alone, 
but also environmental and intrinsic factors, and circadian rhythm is one of them. In 
order to adapt to the 24-hour light and dark cycle in the external environment to optimize 
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activities, mammals have developed self-sustaining endogenous biological clocks named 
internal circadian clocks.  
A great amount of evidence has discovered an association between circadian 
rhythm and metabolism, and that circadian biology is an underlying factor in the 
epidemic occurrence of obesity and diabetes, other than excessive dietary intake and lack 
of physical exercise habits of the population. Night-shift workers have been found to 
display higher BMI, exaggerated postprandial glucose response and abnormal blood 
lipid profile, and are more likely to develop metabolic disorders [50-52]. People with a 
typical sleep duration of less than 6 hours more than 9 hours experience higher rate of 
impaired glucose tolerance and higher prevalence of T2DM [53]. Interestingly, 
proinflammatory cytokine levels of TNF-α and IL-6 in the morning are significantly 
higher in patients with apnea [54]. Clock mutant mice are obese, exhibit disrupted 
feeding rhythm, and develop hyperlipidemia, hyperglycemia, and other metabolic 
syndrome [55]. In rodents and humans, an attenuation of circadian control of glucose 
metabolism and insulin action may promote T2DM and  incidence of other metabolic 
disorders; while in some tissue of diabetic animals, oscillation of circadian clock genes 
are altered [5, 6].  
 At the molecular level, circadian clocks are governed by a self-sustaining 
transcriptional and translational feedback loop involving core circadian clock genes, 
which activate or suppress their own expression. These core clock genes include 
circadian locomotor output cycles kaput (Clock), brain and muscle-ARNT-like 1 
(Bmal1), Period1 (Per1), Period2 (Per2), Period3 (Per3), Cryptochrome1 (Cry1), and 
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Cryptochrome2 (Cry2). Clock and Bmal1 encode for CLOCK and BMAL1 proteins, 
which will form a heterodimer complex that serves as the positive limb of the feedback 
loop and drives the oscillatory function of the circadian clock. Upon binding to the 
enhancer E-box sequence in the promoter region, the CLOCK:BMAL1 heterodimer will 
activate transcription of repressor genes including Per1, Per2, Per3, Cry1, and Cry2, 
which contribute to the negative limb of the feedback loop. When high levels of PERs 
and CRYs are produced and released into the cytoplasm, they dimerize and transfer to 
the nucleus to suppress CLOCK-BMAL1-stimulated transcription. Because of the 
continuous operation of the regulatory feedback loop, the circadian mechanism oscillates 
with a rhythm. This core feedback loop is supported by another ancillary loop that is 
regulated by reverse erythroblastosis virus (Rev-erbα), which suppresses Bmal1 
expression (Figure 4) [6, 56-60].  
Besides central circadian clock which exists in the suprachiasmatic nucleus 
(SCN) in the hypothalamus, peripheral clocks are located in peripheral tissues such as 
liver, adipose tissue, pancreas, heart and skeletal muscle. By interacting with each other, 
central and peripheral clocks regulate eating behavior and metabolic functions in these 
key organ systems [61]. The existence of a fully functional circadian clock within the 
adipose tissue has been investigated in several studies, indicated by the oscillation of the 
expression of core clock genes, including Bmal1, Clock, Per1, Per2, Cry1, Cry2, and 
Rev-erbα [7, 62, 63]. Disruption of Bmal1 reduced adipocyte differentiation and lipid 
storage in adipocytes in vivo and in vitro, and mice lack of Per2 displayed disrupted lipid 
metabolism and lipid profile. More studies have presented that in the adipose tissue in 
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humans and mice models, circadian clock genes play a role in the regulation of 
adiposity, adipogenesis, lipogenesis, fatty acid oxidation, as well as lipolysis [61-65]. 
Therefore, it is meaningful to discover the circadian rhythms in adipocytes and 
investigate whether treating adipocytes at different circadian times could generate 
differential effects in order to get implications on time of drug delivery in regarding to 
obesity and diabetes. 
 
 
 
Figure 4. Transcriptional-translational feedback loop of core clock genes. [56, 60] 
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3. MATERIALS AND METHODS 
 
The hypothesis of this study is that PFKFB3/iPFK2 is involved in the beneficial 
effects of metformin treatment in adipocytes on the aspects of insulin resistance and 
inflammatory response, and treating adipocytes with pioglitazone at different circadian 
times lead to different extent of effects on insulin resistance and inflammatory response. 
The objectives of this study are: 1. Determine the beneficial effect of metformin 
on adipocytes; 2. Determine the involvement of PFKFB3/iPFK2 in effect of metformin 
and its possible mechanism; 3. Determine the circadian rhythm in adipocytes; 4. 
Determine the different effect of pioglitazone at different circadian times. 
 
3.1 Cell culture 
 Wild-type 3T3-L1 adipocyte cell line was used in this study, as well as stable 
PFKFB3/iPFK2-knockdown (iPFK2-KD) and PFKFB3/iPFK2-Control (iPFK2-Ctrl) 
3T3-L1 adipocytes. Preadipocytes were first cultured in high glucose Dulbecco’s 
modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS), 100 
units/ml penicillin and 100 µg/ml streptomycin at 37°C with 5% CO2 in a humidified 
incubator. Fresh medium was changed every other day until cells were confluent.  
Two days after the cells became confluent, the differentiation was induced with 
growth medium containing 10 µg/ml insulin, 1 µM dexamethasone, and 0.5 mM 3-
isobutyl-1-methylxanthine (designated Day 0) for 48 hours. Then, cells were maintained 
in growth medium with 1 µg/ml insulin, with medium being refreshed every other day 
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for additional 4 days, followed by another incubation of 48 hours in growth medium 
without supplementation of insulin. Cells were treated on Day 8 after full differentiation. 
 3T3-L1 adipocyte cell lines were previously established in Dr. Chaodong Wu’s 
lab. Stable iPFK2-KD and iPFK2-Ctrl cell lines were generated by the transfection of 
predifferentiated 3T3-L1 cells with plasmids containing shRNA against mouse PFKFB3 
and shRNA vector respectively with Lipofectamine 2000 Transfection Reagent 
following manufacturer’s protocol [4]. To confirm the knockdown of PFKFB3/iPFK2, 
western blot was used to examine PFKFB3/iPFK2 expression for both iPFK2-KD and 
iPFK2-Ctrl adipocytes. 
 
3.2 Cell treatment 
3.2.1 Metformin experiments 
Different treatments were performed for determination of the best dose and time 
course for metformin on adipocytes. 5 µM, 50 µM and 500 µM of metformin were 
selected to be added to differentiated 3T3-L1 adipocytes for the best dose under 
stimulation of lipopolysaccharide (LPS). After determining the best dose, metformin was 
treated for different lengths of time (0 hr, 1 hr, 6 hr, 24 hr and 48 hr) for the most 
effective time course under LPS stimulation. Metformin and LPS were prepared with 
PBS as solvent, so PBS was used as control group, and was considered as 0 µM and 0 hr 
of metformin treatment. LPS was added 30 min before harvest for protein samples at 100 
ng/ml, and 6 hours before harvest for RNA samples at 20 ng/ml. All cells were harvested 
at the same time. 
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After the confirmation of the most effective dose and time course of metformin 
treatment, metformin was used to treat fully differentiated iPFK2-KD and iPFK2-Ctrl 
adipocytes. Cells were divided into different sets to investigate inflammatory response 
and insulin signaling response. For inflammatory study, 50 µM metformin was added for 
24 hr to iPFK2-KD and iPFK2-Ctrl cells, and same volume of PBS was added in another 
set as control. 100 ng/ml LPS was added to signal inflammatory response, and same 
volume of PBS was added as control. LPS was added 30 min before harvest for protein 
samples, and 6 hours before harvest for RNA samples. For insulin signaling response, 
50µM metformin and PBS were added for 24 hr to iPFK2-KD and iPFK2-Ctrl cells, and 
100 nM insulin and PBS were added 30 minutes before harvest for protein samples. 
After each treatment, cells were washed twice with cold PBS before harvest for 
protein samples. Protein samples were harvested with cell lysis buffer (20 mM Hepes, 
100 mM sodium fluoride, 10 mM sodium pyrophosphate, 1% NP-40, 0.1% SDS, 2 mM 
EDTA, 2 mM Na Vanadate, pH 7.4), and RNA samples were harvested with RNA 
STAT-60 (Tel-Test, Inc., Friendswood, TX) following manufacture’s protocol, without 
washing with cold PBS. Protein samples were analyzed with western blot, and RNA 
samples were analyzed with RT-PCR as described in the following. 
3.2.2 Circadian experiments 
 After reaching full differentiation, adipocytes needed to be synchronized by a 
change of growth medium to DMEM with 50% horse serum for a serum shock. After 2 
hr, this medium was changed to DMEM containing 5% FBS for 1 hr, followed by a 
change to DMEM supplemented with 10% FBS for 2 hr. After 2 hr, this was designated 
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to be ZT 0, where the medium was changed back to growth medium. Protein and RNA 
samples of adipocytes were harvested at ZT 1, ZT 7, ZT 13, and ZT 19 for an analysis of 
the existence of circadian rhythm within adipocytes. 
After examining the circadian rhythm within adipocytes, 100 ng/ml pioglitazone 
(Pio) was treated to synchronized cells at ZT 7 and ZT 19 for 48 hr, and same volume of 
DMSO was added as control because Pio was dissolved in DMSO. To investigate 
inflammatory response and insulin signaling response, 100 ng/ml LPS and 100 nM 
insulin were added 30 min before harvest, with PBS being control. Protein samples were 
harvested with cell lysis buffer, and were then analyzed with western blot as described 
below. 
 
3.3 Protein isolation and preparation of protein samples 
After protein samples were harvested with cell lysis buffer, they were left frozen 
overnight at -80°C. Protein samples were purified by getting the supernatant after 
centrifuge at 4°C at 14,000 rpm. The concentration of the samples was measured with 
Micro BCA Protein Assay Kit (Thermo scientific, USA) and was quantified with infinite 
M200 (Tecan, Switzerland) at 562 nm absorbance. Samples with the same protein 
concentration were prepared with addition of lysis buffer, loading buffer and DTT, and 
were boiled for 5 min before storage at -80°C. 
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3.4 Western blot analysis 
 Protein samples were loaded to 8% sodium dodecyl sulfate polyacrylamide gels 
(SDS-PAGE) to be separated by electrophoresis, and then the gels were transferred onto 
PVDF membranes at 25V for 30 min. The membranes were blocked with 5% skim milk 
in TBS for 4 hrs, and incubated with a certain primary antibody at 4°C overnight. 
Primary antibodies were diluted 1000 times with 5% BSA in TBS. After 3 times of 
washing with TBS, membranes were incubated in a 1:7,500 goat anti-rabbit secondary 
antibody for 1.5 hrs. After another 3 times of 10 min wash, membranes were detected 
with Western chemiluminescent reagent under CCD Camera (Cascade II:512, 
Photometrics, Tucson, AZ). The levels of JNK, phospho-JNK (p-JNK), NF-κB (p65), 
phospho-NF-κB (Pp65), Akt, phosphor-Akt (p-Akt), AMPK, phospho-AMPK (p-
AMPK) and PFKFB3 were analyzed for both studies, with circadian studies measuring 
additional CLOCK and Bmal1. GAPDH was used as a total control.  
 
3.5 RNA isolation and RT-PCR 
 Total RNA of cells were extracted from harvested cells using STAT-60. RNA 
concentrations were measured using Nanodrop 2000 Spectrophotometer (Thermo 
Scientific) and reverse transcribed into cDNA samples accordingly with GoScriptTM 
Reverse Transcription System (Promega). The relative expression levels were measured 
through RT-PCR using Power SYBR Green under Roche LightCycler II. The mRNA 
levels analyzed included PFKFB3, TNF-α, IL-1β, IL-6, adiponectin, TLR-4, resistin, and 
MCP-1 for metformin studies, and PFKFB3, CLOCK, BMAL1, Per1 and Per2 for 
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circadian studies. The variability in the mRNA expression level was normalized with 
ribosomal 18S RNA amplifications [66]. 
 
3.6 Statistical analysis 
 Statistical data were presented as means ± standard error (SE). Comparisons 
between two groups of data were analyzed by two-tailed Student’s t-tests, where p<0.05 
was considered significant. Significant differences at p<0.05, p<0.01 and p<0.001 
compared to negative controls are indicated by “*”, “**” and “***”, or “†”, “††”, and 
“†††”, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
 
4. RESULTS AND DISCUSSIONS 
 
4.1 Involvement of PFKFB3/iPFK2 in beneficial effect of metformin on adipocytes 
4.1.1 Dose and time effect of metformin on adipocyte inflammatory response 
 To identify the most effective dose and time course of metformin treatment in 
vitro, wild-type 3T3-L1 adipocytes were treated with metformin at increasing 
concentrations at 5 µM, 50 µM and 500 µM, and for 0h, 1h, 6h, 24h and 48h. All the 
cells were harvested at the same time, and 100 ng/ml LPS was used to induce 
inflammatory response.  
In absence of metformin, LPS induced inflammatory response through the 
phosphorylation of JNK1 (p46), JNK2 (p54) and NF-κB. When different doses of 
metformin were added to the cells, western blot analysis did not show much difference 
on different doses (Figure 5A), but different time courses showed significant difference. 
Interestingly, metformin treatment showed a rhythm in anti-inflammatory effect, with 
1h, 24h and 48h being effective in reducing phosphorylation of JNK, and 6h being not 
effective. Under LPS induction, there was inhibition of phosphorylation of JNK1 and 
JNK2 with metformin treatment for 1h, 24h and 48h. 24h of metformin treatment 
seemed to suppress phosphorylation of NF-κB from the western blot results (Figure 5B). 
The quantification of the densitometry of their expressions was performed under ImageJ 
software. Metformin treatment groups were compared with LPS-Met 0h group to 
determine the anti-inflammatory effect of metformin. Adipocytes significantly decreased 
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p-JNK expression when treated with metformin for 1h, 24h and 48h (Figure 5C), and 
significantly decreased p-NF-κB expression with metformin for 24h (Figure 5D).  
 
 
 
Figure 5. Metformin inhibits JNK phosphorylation time-dependently in 3T3-L1 
adipocytes. 
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4.1.2 Dose-dependent and time-dependent effect of metformin on adipocytes gene and 
cytokine expression 
 In addition to the protein samples, RNA samples for dose and time treatments 
were harvested and analyzed with RT-PCR. Based on previous results, LPS-Met 1h 
group was not included in RT-PCR because of less significant differences. The mRNA 
expressions measured included proinflammatory cytokines TNF-α, IL-1β and IL-6, 
major adipokine adiponectin, and our interested gene PFKFB3. Their relative mRNA 
expression was determined with 18s as the control. Data are presented as mean ± SE (n = 
3 unless specified otherwise). * P < 0.05, ** P < 0.01, *** P < 0.001 for significance 
level in comparison between metformin dose treatment groups and LPS-Met 0 µM or 
LPS-Met 0h group. 
 As expected, the relative TNF-α expression increased when induced with LPS 
(LPS-Met 0 µM) compared to basal (PBS-PBS) in absence of metformin. This increase 
in TNF-α expression appeared to be ameliorated with treatment of metformin when at 
higher doses, with Met at 50 µM being significantly effective in reducing expression 
level of TNF-α (Figure 6A). Expression levels of IL-1β displayed similar pattern. The 
increase in relative IL-1β expression in LPS-Met 0 µM group was inhibited with higher 
doses of metformin treatment, with a concentration of 50 µM (n=2) being significantly 
effective. Meanwhile, low concentration of metformin of 5 µM led to a 2-fold increase in 
IL-1β expression compared to LPS-Met 0h group (Figure 6B). The relative expression 
levels of IL-6, however, did not exhibit similar results. IL-6 expression increased with 
induction of LPS as expected, but when metformin was added to adipocytes under LPS 
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stimulation, it not only showed limited effect in inhibiting IL-6 expression, but increased 
IL-6 expression significantly with increase in metformin concentration when compared 
with LPS-Met 0 µM group. This effect was strongest when the concentration of 
metformin was 500 µM (Figure 6C). 
 In adiponectin expression, it was expected that LPS induction will decrease 
adiponectin expression compared to basal, and metformin was expected to increase 
adiponectin relative expression compared to LPS-Met 0 µM group. However, metformin 
seemed to have limited effect on adiponectin expression. Due to the high standard errors 
within each group, the results of differences in adiponectin expression were not 
significant among different groups (Figure 6D). 
Metformin treatment significantly increased PFKFB3 expression when at higher 
doses, with p-values of 0.00014 and 0.00015 for 50 µM and 500 µM metformin. 
PFKFB3 was highest expressed at 50 µM metformin (Figure 6E). This indicates that 
PFKFB3 expression is induced with effective metformin treatment, and that 
PFKFB3/iPFK2 may be involved in the action of metformin in adipocytes. 
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Figure 6. Dose-dependent effect of metformin on adipocyte gene expression. 
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The relative mRNA expression levels of proinflammatory cytokines for different 
metformin time courses were also examined through RT-PCR. Similar to the results in 
dose response, TNF-α and IL-1β displayed similar trend in regards to time response to 
metformin. In absence of metformin treatment, LPS induction stimulated upregulation in 
expression of proinflammatory cytokines TNF-α and IL-1β as expected. When 
metformin was added with the presence of LPS for all of these, this increase in cytokine 
expression was significantly inhibited. For both TNF-α and IL-1β, the inhibition of their 
expression was most effective when metformin was treated for 24 hr (Figure 7A and B). 
The expression level of IL-6 under metformin treatment was still to our surprise. Even 
though IL-6 expression increased under LPS induction when no metformin was treated, 
improvement was only seen when length of metformin treatment was 6h. Metformin did 
not show improvement for LPS-Met 24h and LPS-Met 48h groups, but increased IL-6 
expression. IL-6 expression was significantly higher than expected, especially for LPS-
Met 24h group (Figure 7C). 
In adiponectin expression, LPS induction appeared to decrease adiponectin 
expression in absence of metformin as expected, but this change was not significant. 
Longer length of metformin treatment at 24h and 48h showed a trend in recovering the 
expression levels of adiponectin to basal levels, but due to standard errors, this 
improvement was not statistically significant (Figure 7D).  
In different time courses of metformin treatment, PFKFB3 expression 
significantly increased compared to LPS-Met 0h group. PFKFB3 was highest expressed 
when metformin was treated for 24h (Figure 7E). The effect of metformin treatment on  
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Figure 7. Time-dependent effect of metformin on adipocyte gene expression. 
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PFKFB3 expression coincided with dose and time course treatments, leading to our 
hypothesis that PFKFB3/iPFK2 is involved in effective metformin treatment. 
When the results in the previous section and this section are taken together, when 
adipocytes are treated with metformin with a concentration of 50 µM for 24 hours, the 
results were most significant in the aspect of decreasing inflammatory response and 
proinflammatory cytokine expression. Therefore, in later experiment, metformin of 50 
µM for 24 h was selected as the most effective dose and time to treatment of 3T3-L1 
adipocytes. 
4.1.3 Confirmation of the knockdown of PFKFB3/iPFK2 in adipocytes 
 After the determination of time and dose of metformin treatment, the 
involvement of PFKFB3/iPFK2 in the anti-inflammatory and insulin-sensitizing effect of 
the treatment in adipocytes was then explored with PFKFB3/iPFK2-Ctrl and 
PFKFB3/iPFK2-KD adipocytes. A western blot was first run to confirm the knockdown 
of PFKFB3/iPFK2. As expected, the knockdown of PFKFB3/iPFK2 was evidenced by 
significantly lower levels in iPFK2 in iPFK2-KD adipocytes compared to iPFK2-Ctrl 
adipocytes, regardless of the treatment. In iPFK2-Ctrl cells, PFKFB3/iPFK2 level was 
higher in PBS-Met group than that in PBS-PBS group after standardized with GAPDH, 
but this difference was not significant. Compared with that in iPFK2-Ctrl adipocytes, 
PFKFB3/iPFK2 did not increase, but tended to decrease with metformin treatment in 
iPFK2-KD adipocytes with a p-value of 0.0532 (Figure 8). 
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Figure 8. Confirmation of the knockdown of PFKFB3/iPFK2 in iPFK2-KD 
adipocytes. 
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4.1.4 A disruption of PFKFB3/iPFK2 in 3T3-L1 adipocytes could impair the anti-
inflammatory effect of metformin  
 To study the role of PFKFB3/iPFK2 in metformin treatment, the difference in 
amelioration of inflammatory response under metformin treatment was first investigated. 
Both iPFK2-Ctrl and iPFK2-KD cells were treated with metformin for 24 hours with a 
concentration of 50 µM. Prior to harvest, inflammatory response was induced by LPS 30 
minutes before harvest for protein samples, and 6 hours before harvest for RNA samples. 
In western blots for analysis of protein samples, changes in levels and phosphorylation 
states of JNK and NF-κB among different treatment groups were measured for iPFK2-
Ctrl and iPFK2-KD adipocytes. mRNA levels of proinflammatory markers and 
adipokines were quantified with RT-PCR. 
 Even though the changes in phosphorylation state of NF-κB was undetectable in 
this experiment, the western blots results showed that in each group of different 
treatments, phosphorylation of JNK in iPFK2-KD adipocytes was drastically higher than 
that in iPFK2-Ctrl cells. The phosphorylation of JNK was quantified by densitometry 
and normalized by GAPDH. This confirmed that PFKFB3/iPFK2 contributes to anti-
inflammatory response in adipocytes, and that a disruption of PFKFB3/iPFK2 could lead 
to inflammatory response through activation of JNK. When iPFK2-Ctrl was treated with 
metformin, phosphorylation of JNK decreased compared to PBS control with or without 
LPS stimulation. However, this improvement in JNK phosphorylation was not present in 
iPFK2-KD adipocytes (Figure 9). Thus, PFKFB3/iPFK2 was essential in the action of 
metformin in inhibiting the activation of JNK pathway. 
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Figure 9. Anti-inflammatory effect of metformin on iPFK2-Ctrl and iPFK2-KD 
cells. 
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4.1.5 A disruption of PFKFB3/iPFK2 in 3T3-L1 adipocytes could impair effect of 
metformin treatment on expression of cytokines 
 The harvest and analysis of the RNA samples were described in above section. 
Data are presented as mean ± SE (n = 3). * p<0.05, ** p<0.01 and *** p<0.001 for 
comparison of effect of metformin treatment within isogenic adipocytes, and † p<0.05, 
†† p<0.01 and ††† p<0.001 for comparison between iPFK2-Ctrl and iPFK2-KD 
adipocytes with same treatment. 
 When both iPFK2-Ctrl and iPFK2-KD adipocytes were treated with metformin 
for 24 hours with a concentration of 50 µM, with or without LPS induction, changes of 
expression levels of proinflammatory markers showed similar pattern. When iPFK2-Ctrl 
cells were treated with metformin without stimulation of LPS, expression levels of TNF-
α, IL-1β, MCP-1 and TLR-4 significantly decreased. When induced with LPS, these 
proinflammatory markers’ expression was enhanced in PBS-LPS group. IL-6 showed 
some trend of amelioration in this increase in expression levels, but this improvement 
was not significant. On the contrast, when iPFK2-KD adipocytes were treated with 
metformin without stimulation of LPS, relative mRNA expression levels of TNF-α, IL-6, 
MCP-1 and TLR-4 significantly increased. Under LPS stimulation, expressions of 
proinflammatory markers increased as expected. Interestingly, metformin treatment not 
only did not show improvement in this enhanced expression, but appeared to exacerbate 
them. In iPFK2-KD cells stimulated with LPS, metformin treatment increased MCP-1 
expression with a significant p-value of 0.0159, and increased TLR-4 expression with a 
p-value of 0.0784 compared with PBS-LPS group (Figure 10). 
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Figure 10. Effect of metformin on proinflammatory markers expression of iPFK2-
Ctrl and iPFK2-KD cells. 
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4.1.6 Knockdown of PFKFB3/iPFK2 in 3T3-L1 adipocytes impaired the insulin-
sensitizing effect of metformin 
 As stated previously, both iPFK2-Ctrl and iPFK2-KD adipocytes were treated 
with 50 µM metformin for 24 hours. Prior to harvest, insulin signaling response was 
explored with or without addition of insulin 30 minutes before harvest of protein 
samples. Changes in levels and phosphorylation states of Akt were used to observe 
insulin signaling response, quantified by ratio of p-Akt to total Akt, normalized by 
GAPDH. 
 In every treatment group in this study, iPFK2-KD adipocytes displayed a marked 
decrease of phosphorylation of Akt compared to iPFK2-Ctrl cells. iPFK2-Ctrl adipocytes 
exhibited a obvious increase in insulin-stimulated Akt phosphorylation in metformin 
treatment groups (Met-PBS and Met-Ins) compared to PBS control (PBS-PBS and PBS-
Ins respectively), indicating the insulin-sensitizing effect of metformin in adipocytes. 
However, when PFKFB3/iPFK2 was disrupted, this beneficial effect of metformin was 
impaired. In iPFK2-KD cells, metformin did not improve insulin signaling in basal 
conditions in absence of insulin, and furthermore, showed a tendency to inhibit insulin 
signaling in insulin-stimulated condition (Figure 11). 
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Figure 11. Effects of metformin on insulin signaling of iPFK2-Ctrl and iPFK2-KD 
cells. 
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4.1.7 AMPK phosphorylation may be a potential pathway involvement of 
PFKFB3/iPFK2 in metformin treatment in adipocytes 
 Since the data above suggested that PFKFB3/iPFK2 was involved in the 
metformin action in anti-inflammatory and insulin-sensitizing aspects, we wanted to 
explore the possible mechanism underlying this involvement. Because of the highly 
activated AMPK pathway in metformin action was established in liver and muscle in 
many studies, and that AMPK is the upstream of PFKFB3 in its modulation [67], we 
hypothesized that in adipocytes, the involvement of PFKFB3/iPFK2 was also through 
the phosphorylation state of AMPK. Therefore, p-AMPK and AMPK levels were 
measured in our study.  
 In dose and time course effect of metformin, PFKFB3/iPFK2 levels appeared to 
increase with metformin treatment. However, phosphorylation of AMPK under LPS 
stimulation did not alter much with different doses and time course of metformin 
treatment, with metformin at 50 µM and 6 h being slightly higher than other 
concentration and time courses (Figure 12). 
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Figure 12. Dose-dependent and time-dependent effect of metformin on 
PFKFB3/iPFK2 and phosphorylation of AMPK. 
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 When comparing the AMPK phosphorylation states in iPFK2-Ctrl and iPFK2-
KD adipocytes under metformin treatment, the phosphorylation of AMPK on iPFK2-Ctrl 
cells was markedly increased with metformin treatment, but was not altered in iPFK2-
KD cells (Figure 13). In iPFK2-Ctrl cells, AMPK was phosphorylated for metformin to 
take action; but when in PFKFB3/iPFK2-disrupted conditions, AMPK was not activated. 
This suggested that AMPK phosphorylation might be a potential pathway of how 
PFKFB3/iPFK2 was involved in metformin treatment in adipocytes. 
 
 
 
Figure 13. Metformin effect on AMPK phosphorylation on iPFK2-Ctrl and iPFK2-
KD cells. 
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4.2 Temporal effect of pioglitazone on 3T3-L1 adipocytes 
4.2.1 3T3-L1 adipocytes displayed circadian rhythms 
 In the first set of experiment, we first wanted to confirm the existence of 
circadian rhythm within 3T3-L1 adipocytes by examining the expression of core clock 
genes and levels of clock proteins. The protein levels of CLOCK, BMAL1 and 
PFKFB3/iPFK2 were measured by western blot of the protein samples that we harvested 
at different circadian times. RT-PCR was utilized to investigate the quantitative 
expression levels of core clock genes, including Clock, Bmal1, Per1, Per2, as well as our 
interested gene PFKFB3.  
 After normalizing with GAPDH, both CLOCK and BMAL1 exhibited 
oscillations in their protein levels, with ZT1 and ZT19 being higher, and ZT7 and ZT13 
being lower. The magnitude of oscillation in CLOCK was smaller to that in BMAL1. 
We also measured the protein levels of PFKFB3/iPFK2, which did not display obvious 
changes at different circadian times (Figure 14).  
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Figure 14. Levels of core clock proteins through different circadian times. 
 
 
Relative mRNA expression of core clock genes was shown in Figure 15, with * p 
< 0.05, ** p < 0.01 and *** p < 0.001 for significance level in comparison with ZT1. 
Clock and Bmal1 displayed similar circadian oscillation, evidenced by a decreased 
expression at ZT13 and markedly increased expression at ZT19 (Figure 15). Per 1 
exhibited some oscillation, but expression levels at ZT7, ZT13 and ZT19 were not  
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Figure 15. Expression of core clock genes at different circadian times. 
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statistically significant different from ZT1. Expression of Per2 was rhythmic with a 
similar patter to Clock, except that the magnitude of amplification was smaller. To our 
surprise, Clock and Bmal1 circadian oscillation were not obviously antiphase to the 
rhythm exhibited by Per1 and Per2. PFKFB3, our interested gene, also displayed 
noticeable rhythmic oscillation in its expression, with its peak expression at ZT19 and 
nadir expression at ZT7. 
Since all of the genes examined displayed a peak expression at ZT19, ZT19 was 
selected as one treatment time point for the following study. To ensure a 12-hour 
treatment window, ZT7, as another treatment time point. The relative expression of the 
majority of our genes were significantly different at ZT7 and ZT19, indicated by † p-
value<0.05, †† p-value<0.01 and ††† p-value<0.001.  
4.2.2 Treating 3T3-L1 adipocytes with pioglitazone at different circadian times may 
have different inflammatory response 
 After proving the circadian oscillation in wild-type 3T3-L1 adipocytes among 
core circadian components, our aim is to explore that whether treating cells with 
pioglitazone at different circadian times could lead to differential results. As stated 
previously, ZT7 and ZT19 were designated as two circadian time points for pioglitazone 
treatment based on our results in the last section. After synchronization, pioglitazone 
was treated to 3T3-L1 adipocytes for 48 hours. LPS was added 30 minutes to induce 
inflammatory response.  
As shown in Figure 16, without addition of any treatment to adipocytes, DMSO-
PBS group exhibited lessened inflammatory state at ZT19, indicated by lower levels of  
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Figure 16. Anti-inflammatory effect of pioglitazone on adipocytes at ZT7 and ZT19. 
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JNK phosphorylation. When cells were stimulated with LPS, p-JNK increased as 
anticipated, to an extent that was similar for circadian times, suggesting that LPS 
induced a stronger inflammatory response at ZT19. Pioglitazone treatment generated 
differential anti-inflammatory effects at two time points, indicated by remarkably 
lowered phosphorylation level of JNK at ZT19, when inflammatory response was 
stronger. This effect was not as strong at ZT7. There was no marked difference in 
changes of p-NF-κB (Figure 16). 
4.2.3 Treating 3T3-L1 adipocytes with pioglitazone at different circadian times did not 
alter insulin-sensitizing effect  
To investigate the temporal effect of pioglitazone in insulin sensitivity, similarly, 
after synchronization, pioglitazone was treated to 3T3-L1 adipocytes at ZT7 and ZT19 
for 48 hours. Insulin was added 30 minutes prior to harvest to stimulate insulin signaling 
response. Proteins samples were analyzed by western blot. 
Adipocytes displayed different levels of Akt phosphorylation at basal conditions 
(DMSO-PBS), with higher p-Akt levels at ZT19. Under insulin stimulation, p-Akt 
increased at ZT7 and ZT19 to an extent that was similar for both circadian times, 
indicating that adipocytes were more responsible to insulin at ZT7. However, similar 
phosphorylation levels of Akt suggested that the addition of pioglitazone did not 
markedly increase insulin signaling at ZT7 and ZT19 (Figure 17). 
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Figure 17. Insulin-sensitizing effect of pioglitazone on adipocytes at ZT7 and ZT19. 
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5. SUMMARY AND CONCLUSIONS 
 
5.1 Summary 
5.1.1 Involvement of PFKFB3/iPFK2 in beneficial effects of metformin on adipocytes  
Treating 3T3-L1 with metformin at 50 µM for 24 hours could ameliorate the 
inflammatory response to LPS induction, evidenced by phosphorylation of JNK and NF-
κB, and expression of proinflammatory cytokines TNF-α and IL-1β.  
In western blot analysis for protein samples and RT-PCR for RNA samples, 
compared with that in iPFK2-Ctrl adipocytes, metformin did not exhibit anti-
inflammatory response when PFKFB3/iPFK2 was knockdown. In iPFK2-KD cells, 
phosphorylation state of JNK was not improved with metformin group, and relative 
mRNA expression of TNF-α, IL-1β, IL-6, MCP-1 and TLR-4 was not reduced under 
metformin treatment. These data suggested that disruption of PFKFB3/iPFK2 weakened 
the anti-inflammatory effect of metformin in adipocytes. In PFKFB3/iPFK2-Control 
(iPFK2-Ctrl) adipocytes, metformin treatment was shown to have significant insulin-
sensitizing effect, evidenced by an increase in p-Akt/Akt signaling. In contrast, insulin 
sensitivity was not improved, but evidently impaired under metformin treatment on 
iPFK2-KD adipocytes.  
In wild-type 3T3-L1 adipocytes, PFKFB3 was upregulated with metformin 
treatment under LPS stimulation, shown by a marked increase in relative mRNA 
expression, suggesting its potential involvement in metformin action. Meanwhile, the 
phosphorylation of AMPK, the upstream of PFKFB3, in iPFK2-Ctrl adipocytes was 
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increased with metformin treatment, but did not alter much in iPFK2-KD cells. This 
indicated the AMPK pathway as the mechanism of involvement of PFKFB3/iPFK2 in 
metformin treatment. 
5.1.2 Temporal effects of pioglitazone on adipocytes 
In 3T3-L1 adipocytes, circadian rhythm was observed in both protein samples 
and RNA samples harvested at different circadian times. Temporal variation for protein 
levels was displayed in CLOCK and BMAL1 with similar patterns. Relative mRNA 
expression of several clock genes Clock, Bmal1, Per1 and Per2 exhibited oscillation. 
PFKFB3 also showed a rhythmic expression through different times.  
Under LPS stimulation, 3T3-L1 adipocytes experienced more inflammatory 
response at ZT19. Pioglitazone treatment at ZT 19 was more effective in reducing 
inflammatory response through dephosphorylation of JNK, but changes in 
phosphorylation state of NF-κB were now seen. Even though adipocytes displayed 
differences in insulin signaling in basal conditions, pioglitazone treatment did not show 
significant insulin-sensitizing effect, and no notable differences were seen between 
pioglitazone treatments at different circadian times. 
 
5.2 Conclusions 
 Taken together, the results generated from this study support the hypothesis of 
the beneficial effects of metformin in 3T3-L1 adipocytes and the critical involvement of 
PFKFB3/iPFK2. Metformin treatment on 3T3-L1 adipocytes could increase insulin 
sensitivity and ameliorate inflammatory response through dephosphorylation of JNK and 
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inhibition of proinflammatory cytokine expression. A disruption of PFKFB3/iPFK2 in 
adipocytes impairs the insulin-sensitizing and exacerbates anti-inflammatory effect of 
metformin. This involvement of PFKFB3/iPFK2 in metformin action is possibly through 
the AMPK pathway. 
3T3-L1 adipocytes display an internal oscillation, evidenced by temporal 
variations in levels of core clock proteins and expression of core clock genes. 
Furthermore, 3T3-L1 adipocytes responded circadian time-differently when stimulated 
with LPS and insulin. Anti-inflammatory effect of pioglitazone at ZT19 is more effective 
than that at ZT7, while no significant insulin-sensitizing effect was seen in both time 
points. 
 
5.3 Future experiments 
 According to the generated data, there are some suggestions for future 
experiments in the following: 
1. Using iPFK2-Ctrl and iPFK2-KD mice models to investigate the involvement of 
PFKFB3/iPFK2 in metformin treatment in high-fat diet mice, in regards to 
inflammatory and insulin-sensitizing effects, and activation of AMPK 
2. Since PFKFB3/iPFK2 also displays circadian oscillation in 3T3-L1 adipocytes, 
iPFK2-Ctrl and iPFK2-KD cell lines could be utilized to investigate temporal 
drug effects and the involvement of PFKFB3/iPFK2 
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